Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 5.5% – Time to Sell?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) shares fell 5.5% during mid-day trading on Tuesday . The stock traded as low as $21.61 and last traded at $21.77. 36,787 shares traded hands during mid-day trading, a decline of 87% from the average session volume of 280,797 shares. The stock had previously closed at $23.04.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research note on Monday, November 11th. Raymond James upgraded Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. Oppenheimer increased their price target on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a research note on Monday, November 11th. Finally, TD Cowen initiated coverage on shares of Dianthus Therapeutics in a research report on Friday, December 20th. They set a “buy” rating for the company. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $46.43.

Dianthus Therapeutics Stock Performance

The firm’s 50-day simple moving average is $24.38 and its 200 day simple moving average is $26.60. The company has a market capitalization of $613.25 million, a PE ratio of -8.29 and a beta of 1.74.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.15). Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The company had revenue of $2.17 million for the quarter, compared to analyst estimates of $1.07 million. As a group, equities analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Institutional Trading of Dianthus Therapeutics

A number of institutional investors have recently bought and sold shares of DNTH. Barclays PLC raised its stake in shares of Dianthus Therapeutics by 390.5% during the 3rd quarter. Barclays PLC now owns 41,684 shares of the company’s stock worth $1,141,000 after buying an additional 33,185 shares during the last quarter. Jane Street Group LLC purchased a new position in Dianthus Therapeutics during the third quarter worth $556,000. Wellington Management Group LLP purchased a new position in shares of Dianthus Therapeutics during the third quarter valued at approximately $1,473,000. State Street Corp grew its stake in Dianthus Therapeutics by 101.4% in the 3rd quarter. State Street Corp now owns 821,131 shares of the company’s stock worth $22,483,000 after acquiring an additional 413,425 shares during the period. Finally, Point72 Asset Management L.P. raised its holdings in Dianthus Therapeutics by 151.3% in the 3rd quarter. Point72 Asset Management L.P. now owns 437,700 shares of the company’s stock valued at $11,984,000 after acquiring an additional 263,500 shares during the last quarter. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.